Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats

Journal of Hypertension

Volumn 29, Issue 2, 2011, Pages 290-298

  Rafiq, Kazi ^a   Nakano, Daisuke ^a   Ihara, Genei ^b   Hitomi, Hirofumi ^a   Fujisawa, Yoshihide ^a   Ohashi, Naro ^c   Kobori, Hiroyuki ^c   Nagai, Yukiko ^a   Kiyomoto, Hideyasu ^b   Kohno, Masakazu ^b   Nishiyama, Akira ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b Department of Cardio Renal and Cerebrovascular Medicine ^*  (Japan)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

eplerenone; hydrocortisone; kidney diseases; mineralocorticoid receptor

Indexed keywords

ALBUMIN; ALDOSTERONE; CREATININE; DEXAMETHASONE; EPLERENONE; GLUCOCORTICOID; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR; PHOSPHOTRANSFERASE; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SODIUM PROTON EXCHANGE PROTEIN 1;

ADRENALECTOMY; ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; GLOMERULOSCLEROSIS; HYPERTENSION; KIDNEY INJURY; KIDNEY PARENCHYMA; MALE; MORPHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PODOCYTE; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION;

EID: 78651317494     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834103a9     Document Type: Article

References (37)

1. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63:1791-1800.
2. Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 2004; 43:841-848.
3. Terada Y, Kobayashi T, Kuwana H, Tanaka H, Inoshita S, Kuwahara M, Sasaki S. Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A. J Am Soc Nephrol 2005; 16:2296-2305.
4. Nishiyama A, Yao L, Fan Y, Kyaw M, Kataoka N, Hashimoto K, et al. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 2005; 45:710-716.
5. Onozato ML, Tojo A, Kobayashi N, Goto A, Matsuoka H, Fujita T. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant 2007; 22:1314-1322.
6. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006; 47:1084-1093.
7. Du J, Fan YY, Hitomi H, Kiyomoto H, Kimura S, Kong CZ, et al. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats. Am J Physiol Renal Physiol 2009; 297:F802-F808.
8. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31:451-458.
9. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70:2116-2123.
10. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41:1021-1026.
11. Funder JW. Mineralocorticoid receptors: distribution and activation. Heart Fail Rev 2005; 10:15-22.
12. Funder J, Myles K. Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology 1996; 137:5264-5268.
13. Nagase M, Fujita T. Aldosterone and glomerular podocyte injury. Clin Exp Nephrol 2008; 12:233-242.
14. Kageyama Y, Suzuki H, Saruta T. Role of glucocorticoid in the development of glycyrrhizin-induced hypertension. Clin Exp Hypertens 1994; 16:761-778.
15. Otsuki M, Okabayashi Y, Ohki A, Suehiro I, Nakamura T, Fujii M, et al. Effects of hydrocortisone on glucose- and cholecystokinin-induced insulin release from the isolated perfused rat pancreas. Pancreas 1988; 3:459-464.
16. Vackova Z, Vagnerova K, Libra A, Miksik I, Pacha J, Staud F. Dexamethasone and betamethasone administration during pregnancy affects expression and function of 11 beta-hydroxysteroid dehydrogenase type 2 in the rat placenta. Reprod Toxicol 2009; 28:46-51.
17. Li C, Wang W, Summer SN, Falk S, Schrier RW. Downregulation of UT-A1/ UT-A3 is associated with urinary concentrating defect in glucocorticoidexcess state. J Am Soc Nephrol 2008; 19:1975-1981.
18. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007; 49:355-364.
19. Miyata K, Ohashi N, Suzaki Y, Katsurada A, Kobori H. Sequential activation of the reactive oxygen species/angiotensinogen/renin-angiotensin system axis in renal injury of type 2 diabetic rats. Clin Exp Pharmacol Physiol 2008; 35:922-927.
20. Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, et al. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 2005; 16:703-711.
21. Diah S, Zhang GX, Nagai Y, Zhang W, Gang L, Kimura S, et al. Aldosterone induces myofibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells. Exp Cell Res 2008; 314:3654-3662.
22. Gong D, Lu J, Chen X, Reddy S, Crossman DJ, Glyn-Jones S, et al. A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-beta activation in the kidneys of rats used as a model of diabetes. Diabetologia 2008; 51:1741-1751.
23. Matavelli LC, Huang J, Siragy HM. (Pro)renin receptor contributes to diabetic nephropathy by enhancing renal inflammation. Clin Exp Pharmacol Physiol 2010; 37:277-282.
24. Park J, Leong ML, Buse P, Maiyar AC, Firestone GL, Hemmings BA. Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI 3-kinase-stimulated signaling pathway. EMBO J 1999; 18:3024-3033.
25. Vallon V, Lang F. New insights into the role of serum- and glucocorticoid-inducible kinase SGK1 in the regulation of renal function and blood pressure. Curr Opin Nephrol Hypertens 2005; 14:59-66.
26. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988; 242:583-585.
27. Kitagawa H, Yanagisawa J, Fuse H, Ogawa S, Yogiashi Y, Okuno A, et al. Ligand-selective potentiation of rat mineralocorticoid receptor activation function 1 by a CBP-containing histone acetyltransferase complex. Mol Cell Biol 2002; 22:3698-3706.
28. Rogerson FM, Fuller PJ. Interdomain interactions in the mineralocorticoid receptor. Mol Cell Endocrinol 2003; 200:45-55.
29. Hultman ML, Krasnoperova NV, Li S, Du S, Xia C, Dietz JD, et al. The liganddependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms. Mol Endocrinol 2005; 19:1460-1473.
30. Nishiyama A, Abe Y. Aldosterone and renal injury. Nippon Yakurigaku Zasshi 2004; 124:101-109.
31. Ferrari P. Cortisol and the renal handling of electrolytes: role in glucocorticoid-induced hypertension and bone disease. Best Pract Res Clin Endocrinol Metab 2003; 17:575-589.
32. Koh JM, Kim JY, Chung YE, Park JY, Shong YK, Hong SK, et al. Increased urinary albumin excretion in Cushing's syndrome: remission after correction of hypercortisolaemia. Clin Endocrinol (Oxf) 2000; 52:349-353.
33. Bailey MA, Mullins JJ, Kenyon CJ. Mineralocorticoid and glucocorticoid receptors stimulate epithelial sodium channel activity in a mouse model of cushing syndrome. Hypertension 2009; 54:890-896.
34. Okada H, Kikuta T, Inoue T, Kanno Y, Ban S, Sugaya T, et al. Dexamethasone induces connective tissue growth factor expression in renal tubular epithelial cells in a mouse strain-specific manner. Am J Pathol 2006; 168:737-747.
35. Ong SL, Zhang Y, Whitworth JA. Reactive oxygen species and glucocorticoid-induced hypertension. Clin Exp Pharmacol Physiol 2008; 35:477-482.
36. Tonolo G, Fraser R, Connell JM, Kenyon CJ. Chronic low-dose infusions of dexamethasone in rats: effects on blood pressure, body weight and plasma atrial natriuretic peptide. J Hypertens 1988; 6:25-31.
37. Whitworth JA, Gordon D, Andrews J, Scoggins BA. The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. J Hypertens 1989; 7:537-549.